KAM
BNGO icon

Knightsbridge Asset Management’s Bionano Genomics BNGO Stock Holding History

Knightsbridge Asset Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17
Closed -$15K – 133
2022
Q4 		$15K Hold
17
– – ﹤0.01% 136
2022
Q3 		$18K Buy
+17
New +$22.5K ﹤0.01% 117

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Knightsbridge Asset Management's BNGO Position: Q1 2023 in Review

Knightsbridge Asset Management sold out of Bionano Genomics (BNGO) in Q1 2023, closing a stake of 17 shares — an estimated $15K sold.

Knightsbridge Asset Management first reported a position in BNGO in Q3 2022 and held it in 2 quarters. The position peaked at $18K in Q3 2022. 126 funds tracked by Wall St. Rank hold BNGO as of Q1 2023.

  • Knightsbridge Asset Management reported no remaining Bionano Genomics position as of Q1 2023 after selling out during the quarter.
  • Knightsbridge Asset Management sold 17 Bionano Genomics shares in Q1 2023, an estimated $15K.
  • Knightsbridge Asset Management first reported a position in Bionano Genomics in Q3 2022 and held it in 2 quarters.
  • Knightsbridge Asset Management's Bionano Genomics position peaked at $18K in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2023.

Based on Knightsbridge Asset Management's 13F filing for Q1 2023, filed 12 May 2023.